Cepheid Receives FDA Clearance for Xpert SA Nasal Complete, the First Molecular Test for Simultaneous Detection and Differentiation of S. aureus & MRSA Colonization

SUNNYVALE, Calif., June 8 /PRNewswire-FirstCall/ -- Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® SA Nasal Complete, the first and only molecular test designed for the simultaneous detection and differentiation of both Staphylococcus aureus (SA) and Methicillin-resistant Staphylococcus aureus (MRSA) colonization in less than one hour. The test runs on Cepheid’s GeneXpert® System, the world’s leading molecular platform for accuracy, speed, and ease-of-use.